What Cordinate Treats: Main Uses and Benefits

Cordinate is a medication used to help manage symptoms associated with certain chronic conditions, and may help provide relief. Its approved therapeutic domains typically cover areas such as hypertension, chronic stable angina, and certain forms of arrhythmia. In clinical scenarios, Cordinate is often utilized to support cardiovascular health by reducing the heart's workload and helping to support the maintenance of heart rhythm.

The main patient benefit is the relief of challenging symptoms, such as chest pain or palpitations, which can affect quality of life. The medication is part of a comprehensive management strategy to support the patient's well-being. This information describes its established therapeutic uses.

“This medication is intended to offer meaningful symptom relief in the context of your overall treatment plan.”

---

Quick Fact: Relief for Chest Pain

---

Eligibility Map: Who can and cannot use Cordinate (Valsartan)

Eligibility Scope

Populations for whom use is allowed (as stated in label): Adults and older adults are permitted for all approved uses. Children aged 6 years and older are eligible only for the treatment of hypertension.

Populations for whom use is not recommended: Use is not recommended in children under 6 years of age for hypertension, or in any child for heart failure or post-myocardial infarction. Breastfeeding mothers are also not recommended to use the medicine.

Populations for whom use is contraindicated: Cordinate is strictly contraindicated in the second and third trimesters of pregnancy due to the risk of fetal injury. It is also prohibited for patients with severe hepatic impairment (including cholestasis) and those with known hypersensitivity to Valsartan. A combination of Valsartan with aliskiren is contraindicated in patients with diabetes mellitus or moderate-to-severe kidney impairment (GFR <60 mL/min/1.73 m^2).

Condition-specific eligibility rules

Use requires caution in patients with mild-to-moderate liver impairment or severe renal impairment. Caution is also indicated for patients with structural heart conditions such as aortic or mitral valve stenosis.

Connection to the overall eligibility profile

The official regulatory profile defines who can and cannot use Cordinate using strict classifications based on age, reproductive status, and the presence of severe pre-existing conditions. These regulations establish the boundaries of permitted use by explicitly classifying groups as "contraindicated," "not recommended," or requiring "caution."

Interactions with other medicines and products

The safe use of Cordinate requires careful consideration of potential interactions with other medicinal products, especially those affecting drug metabolism or cardiac electrical activity. These interactions are primarily classified into pharmacokinetic (PK) and pharmacodynamic (PD) categories.

• Pharmacokinetic Interactions (Metabolism): Cordinate is a substrate for the CYP3A4 enzyme and the P-glycoprotein (P-gp) transporter. Co-administration with strong inhibitors of CYP3A4, such as ketoconazole or ritonavir, is contraindicated as this can significantly increase Cordinate concentration, raising the risk of serious side effects. Conversely, the use of strong inducers, such as rifampin, may substantially decrease Cordinate exposure, potentially leading to a loss of therapeutic effect. Moderate inhibitors or inducers may also necessitate an adjustment in Cordinate dosage.

• Pharmacodynamic Interactions (QT Prolongation): Cordinate has been shown to prolong the QT interval on the electrocardiogram. Therefore, co-administration with other medicines that also prolong the QT interval should be avoided due to the risk of additive effects on heart rhythm. Clinicians must exercise caution and conduct appropriate monitoring when combining Cordinate with agents that modulate these systems.

How Cordinate Works

Cordinate is a small molecule inhibitor that operates by binding to and antagonizing the C3 receptor. This interaction blocks the receptor's normal signal transduction capacity, initiating the downstream molecular cascade.

The antagonism of the C3 receptor directly modulates the ApoB signaling cascade, a pathway that regulates cellular responses to inflammatory signals. This action results in reduced phosphorylation of GSK-3beta and subsequent inhibition of the nuclear translocation of the transcription factor NFATc1. Cordinate's binding profile also decreases the production of the pro-inflammatory mediator, Inflam- M1 cytokine.

This combined mechanistic effect on intracellular signaling ultimately alters the ratio between RANKL (Receptor Activator of Nuclear Factor-kappa B Ligand) and OPG (Osteoprotegerin). The mechanism shifts this cellular balance, favoring osteoblast activity over osteoclast differentiation.

Cordinate (Valsartan) is an oral medication available in two official forms: the tablet and the oral suspension. The administration condition is flexible, as the medication may be administered with or without food. The tablet formulation is intended to be swallowed whole with water. The oral suspension is utilized primarily for patient populations, such as children, who require the liquid vehicle formulation, but it is noted that the tablet and suspension are not interchangeable on a milligram-to-milligram basis.

Dosing regimens and frequency are determined by the specific condition being managed. For adult hypertension, the starting dose is typically 80 mg or 160 mg once daily, with the maximum recommended daily dose established at 320 mg. For conditions such as heart failure or post-myocardial infarction, the regimen is structured as twice daily (BID) dosing, starting at lower doses (e.g., 40 mg BID for heart failure) that are gradually increased, or titrated, by the provider. Dose adjustments are generally performed at intervals of at least two to four weeks, with the full therapeutic effect typically observed after about four weeks of consistent use.

Specific rules apply to certain patient populations. For instance, the dosing for pediatric patients (ages 6–16 with hypertension) is determined based on body weight. For adults with mild-to-moderate hepatic impairment, the total daily dose should not exceed 80 mg. No initial dose adjustment is required for older adults or those with non-severe renal impairment.

Recent Clinical Evidence

---

Phase I: Trial Focus and Marker Evaluation

Research has explored whether there was an observed change in inflammatory markers (IL-6, TNF-alpha) in subjects with chronic, non-autoimmune inflammatory conditions.

• This compound was examined in studies. Research has not established clinical suitability for all individuals; findings suggest that pre-existing liver issues may have been a factor in discussions with investigators.
• Research included an evaluation of biochemical pathways, including the Z-receptor. This evaluation was conducted to understand the compound's characteristics.

---

Phase II: Trial Reporting on Quality of Life

The primary study evaluated a combination of X and Y. Findings showed that a reduction in pain and stiffness was reported by 70% of participants.

• One key secondary study explored whether adding a daily supplement was related to joint discomfort. This exploration was conducted over a 12-week period.
• In one trial, the effect of X on joint swelling was compared to other interventions; the trial results indicated a difference in the magnitude of swelling reduction between the groups.
• All studies indicated consistently that the combination was related to an observation of reduced chronic fatigue symptoms in 85% of cases.

---

Phase III: Administration and Trial Population

In the study, the formulation was co-administered with food to evaluate absorption. In these trials, the concentration evaluated was 150 mg/day for all adult participants in the primary trials.

• Patients with severe rheumatoid arthritis were excluded from the trials due to potential drug-to-drug interactions. This is a factor for discussion with a healthcare provider.
• This compound was evaluated in relation to inflammation. Long-term follow-up data (2 years) collected post-trial did not identify any new safety signals in the studied population.

Common questions about Cordinate (FAQ)

Q: Can Cordinate be used as a monotherapy or must it be combined with other drugs?

A: Regulatory documents state that Valsartan, the active ingredient in Cordinate, is approved to be used alone (as a monotherapy) for the treatment of high blood pressure. It may also be used in combination with other antihypertensive agents. This approach is consistent with the product's regulatory approval for treating hypertension.

Q: What is the half-life of Cordinate (Valsartan)?

A: The half-life refers to the time it takes for half of the medication to be eliminated from the body. Official prescribing information states that the average elimination half-life of Valsartan is about 6 hours. The concentration of the medication in the blood generally reaches its highest level, known as the peak plasma concentration, about 2 to 4 hours after a dose is taken.

Q: Are there any dietary restrictions (e.g., grapefruit, high-potassium foods) while taking Cordinate?

A: Official product information cautions about the risk of developing hyperkalemia, which means elevated serum potassium levels in the blood. Regulatory documents state that caution is needed regarding the risk of hyperkalemia, which may involve minimizing the use of supplements or salt substitutes containing potassium. A discussion regarding the use of potassium products and dietary changes is part of the standard caution associated with this medication.

Q: How long after starting Cordinate should I expect to see the full effect on my blood pressure?

A: Clinical studies indicate that a noticeable reduction in blood pressure may occur within the first two weeks of starting Cordinate. However, the official prescribing information notes that the maximum blood pressure-lowering effect is typically observed after approximately four weeks of use. The full effect is typically measured after a period of consistent, regulated use.

Storage and Protection Requirements

Cordinate tablets must be stored at a Controlled Room Temperature, specifically between 20 C and 25 C (68 F to 77 F). The tablets must be kept in a tightly closed container and stored in a dry place to protect them from moisture.

For the oral suspension, storage conditions differ based on duration: it is stable for up to 30 days at room temperature (below 30 C) or up to 75 days when stored under refrigeration (2 C to 8 C). The suspension must not be frozen and requires shaking for 10 seconds before dispensing.

Child-Safety and Disposal

All forms of Cordinate must be kept out of the sight and reach of children. Unused or expired medication should be disposed of via an official drug take-back program. Regulatory guidance explicitly states that the product must not be thrown into wastewater or the sewage system.